IGC Pharma Adds Brooklyn Clinical Trial Site
IGC Pharma announced the addition of Integrative Clinical Trials, located in Brooklyn, New York, as a new clinical site participating in the Company's Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease. Integrative Clinical Trials is a clinical research center conducting studies across a broad range of Central Nervous System disorders, including Alzheimer's disease and mild cognitive impairment. The site is led by Dr. Inna Yuryev-Golger, MD, who serves as Principal Investigator and brings more than 10 years of experience conducting clinical research. Bella Yevseva serves as the Clinical Trial Coordinator.
Get Free Real-Time Notifications for Any Stock
Analyst Views on IGC
About IGC
About the author
ZIM Integrated Shipping Shares Surge 7.6% on Acquisition Proposals
- Surge in Acquisition Proposals: ZIM Integrated Shipping has received multiple competitive acquisition proposals during its strategic review, with the board evaluating these offers to create significant value for shareholders, which is expected to enhance the company's market appeal.
- Stock Price Rebound: Following the announcement, ZIM's shares rose 7.6% in pre-market trading to $21.38, reflecting market optimism about the company's future prospects and potentially attracting more investor interest.
- Enhanced Strategic Value: By actively assessing acquisition proposals, ZIM not only strengthens its market position but also may achieve operational efficiencies through resource integration, thereby delivering higher returns to shareholders.
- Positive Market Reaction: The stock price increase indicates investor confidence in ZIM's potential acquisitions, which could further boost the company's competitiveness and market share in the shipping industry.
IGC Pharma Reaches 65% Enrollment Milestone in Phase 2 CALMA Trial for Alzheimer's Agitation
Trial Progress: IGC Pharma has achieved 65% patient enrollment in its Phase 2 CALMA trial for IGC-AD1, aimed at treating agitation in Alzheimer's disease, with a target of 146 participants.
Agitation in Alzheimer's: Agitation affects over 76% of Alzheimer's patients, leading to significant distress for both patients and caregivers, highlighting the need for new treatment options.
Therapeutic Potential: Interim analyses of IGC-AD1 have shown significant reductions in agitation, indicating its potential as a novel therapy for Alzheimer's dementia.
Recruitment Strategy: The trial's enrollment has been enhanced through a hybrid strategy, with 25% of participants recruited via social media and 75% through clinical sites, aiming for full enrollment by early 2026.
